

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 October 2011 (13.10.2011)

(10) International Publication Number
WO 2011/127322 A1

(51) International Patent Classification:
C12Q 1/00 (2006.01) *H01J 49/00* (2006.01)
C12P 21/06 (2006.01)

(21) International Application Number:
PCT/US2011/031637

(22) International Filing Date:
7 April 2011 (07.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/321,857 7 April 2010 (07.04.2010) US

(71) Applicant (for all designated States except US): **MONUMENTA PHARMACEUTICALS, INC.** [US/US]; 675 West Kendall Street, Cambridge, MA 02142 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COLLINS, Brian, E.** [US/US]; 30 Country Club Drive, Arlington, MA 02474 (US). **DUFFNER, Jay** [US/US]; 29 Lawton Road, Shirley, MA 01464 (US). **BOSQUES, Carlos, J.** [US/US]; 40 Brattle Street #7, Arlington, MA 02476 (US). **BULIK, Dorota, A.** [PL/US]; 240 Hawthorne Street, Malden, MA 02148 (US). **MYETTE, James** [US/US]; 33 Winthrop Street, Waltham, MA 02453 (US).

(74) Agent: **LAWRENCE, Laurie, Butler**; Lando & Anastasi LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))



WO 2011/127322 A1

(54) Title: HIGH MANNOSE GLYCANS

(57) Abstract: Methods and compositions related to high mannose glycans are described.

HIGH MANNOSE GLYCANS

This application claims priority to U.S. Application Serial No. 61/321,857, filed on April 7, 2010. The disclosure of the prior application is considered part of (and is incorporated by reference in) the disclosure of this application.

BACKGROUND OF THE INVENTION

[0001] A typical glycoprotein product differs substantially in terms of complexity from a typical small molecule drug. The sugar structures attached to the amino acid backbone of a glycoprotein can vary structurally in many ways including, sequence, branching, sugar content, and heterogeneity. Thus, glycoprotein products can be complex heterogeneous mixtures of many structurally diverse molecules which themselves have complex glycan structures. Glycosylation adds not only to the molecule's structural complexity but affects or conditions many of a glycoprotein's biological and clinical attributes.

SUMMARY OF THE INVENTION

[0002] The invention is based, at least in part, on methods and compositions related to the analysis and control of high mannose glycan structures (Man4, Man5, Man6, Man7, Man8 and/or Man9 structures) on glycoproteins. The N-linked glycan pathway showing the synthesis of high mannose and complex glycan structures, is shown in Figure 1.

Product analytical methods

[0003] Accordingly, in some aspects, the invention features methods to analyze high mannose structures on a glycoprotein preparation, e.g., methods to identify and/or quantify high mannose glycans or glycoforms. Such methods can be used to measure one or more of: the presence and/or amount of high mannose in a glycan or glycoprotein preparation (e.g., relative to total glycan mass); the relative ratios of high mannose structures [e.g., relative ratios of high mannose species to each other (e.g., relative abundances or ratios of Man4, Man5, Man 6, Man7, Man8 and/or Man9 and isomers thereof), relative ratios of high mannose to hybrid structures, relative ratios of high mannose to complex structures, relative ratios of high mannose to

Attorney Docket No.: M2050-7059WO/M0074WO

fucosylated structures]; the presence or abundance of modified high mannose structures (e.g., the presence or abundance of fucosylated high mannose structures).

[0004] In one such aspect, the invention features a method to analyze (identify and/or quantify) high mannose glycoforms in a glycoprotein mixture, e.g., a glycoprotein preparation. The method includes: (a) providing a glycoprotein-containing sample; (b) optionally performing a buffer exchange to buffer compatible with enzymatic digest and/or mass spectrometry (MS) analysis, (c) removing higher abundance glycans from the glycoprotein sample (e.g., treating the glycoprotein sample with an enzyme that cleaves complex fucosylated glycans from the glycoprotein, e.g., treating with Endoglycosidase F3); (d) optionally reducing and alkylating the sample and/or performing a buffer exchange to buffer compatible with mass spectrometry. In one embodiment, a next step (e) includes identifying and/or quantifying high mannose-containing glycoforms in the treated sample (e.g., by electrophoretic methods such as capillary electrophoresis (CE); reverse phase LC-MS or targeted reverse phase-LC-MS). In certain embodiments in which the theoretical masses of the high mannose-containing glycoforms are known, a targeted MS experiment can be established to only monitor selected set of m/z signatures corresponding to these species. In another embodiment, step (e) alternatively includes identifying and/or quantifying low abundance glycoforms in the treated sample, including but not limited to high mannose glycoforms.

[0005] In one embodiment the method is a high resolution method, e.g., the method separately identifies and/or quantifies individual glycoforms (e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 individual glycoforms) in a glycoprotein mixture.

[0006] In one embodiment the glycoprotein mixture is an antibody preparation, e.g., a pharmaceutical antibody preparation. In one embodiment, the antibody preparation was expressed from a mammalian cell culture.

[0007] In another such aspect, the invention features a method to analyze (identify and/or quantify) high mannose and/or hybrid structures in a glycan or glycoprotein preparation. The method includes (a) providing a glycan or glycoprotein mixture, (b) treating the glycan mixture or glycoprotein mixture with an enzyme that cleaves the exposed terminal mannosidase residues at the non-reducing end of a glycoform, and (c) quantifying the cleaved terminal mannose

Attorney Docket No.: M2050-7059WO/M0074WO

residues. In one embodiment, the quantifying step includes performing quantitative monosaccharide analysis (e.g., by HPLC or GC-MS). In an embodiment, the released terminal mannoses are quantified relative to total glycan mass, thereby analyzing high mannose and/or hybrid structures in a glycan or glycoprotein preparation.

[0008] In one embodiment the glycoprotein preparation is an antibody preparation, e.g., a pharmaceutical antibody preparation. In one embodiment, the antibody preparation was expressed from a mammalian cell culture.

[0009] In some embodiments, an analytical method described herein detects high mannose structures present at low abundance in a glycoprotein preparation, e.g., the method detects high mannose structures, e.g., one or more of Man4, Man5, Man 6, Man7, Man8 and/or Man9, present at less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.3%, 0.1% or less than 0.05% abundance relative to total glycan mass.

[00010] In some embodiments, the method is a high-throughput method, e.g., all the steps of the method can be completed in less than 8, 7, 6, 5, 4, 3, 2 hours per sample; the method can be used to process at least 5 samples per day. In another embodiment, greater than 20, 30, 40, 50, 60, 70, 80, 90 or 100 samples can be run per day using one operator and one instrument per method. In another embodiment, the method requires minimal sample preparation (e.g., sample preparation includes only an optional buffer exchange; does not require multiple clean-up or purification steps, and/or or derivatization procedures).

[00011] In one embodiment, the method is a method run under GMP conditions.

[00012] In one embodiment, the glycoprotein is an immunoglobulin (IgG) (e.g., a therapeutic antibody such as an IgG1, IgG2) or an Ig fusion (e.g., a therapeutic receptor-Fc fusion). Some examples include: bevacizumab, tositumomab, abciximab, alemtuzumab, acritumomab, cetuximab, adalimumab, ranibizumab, gemtuzumab, efalizumab, infliximab, abciximab, rituximab, basiliximab, eculizumab, palivizumab, omalizumab, daclizumab, ibritumomab tiuxetan, certolizumab pegol, daclizumab, eculizumab, muromonab-CD3, natalizumab, panitumumab, ranibizumab, tositumomab, alefacept, etanercept, abatacept.

Attorney Docket No.: M2050-7059WO/M0074WO

[00013] In other embodiments, the glycoprotein is a therapeutic hormone (e.g., FSH), an interferon, an erythropoietin, a colony stimulating factor, or a therapeutic replacement enzyme (e.g., glucocerebrosidase, alpha-galactosidase).

[00014] Methods of the present disclosure may be used for assessment of high mannose structures in one or more stages of development in the production of a therapeutic or other commercially relevant glycoprotein, for example, during host cell selection, clonal selection, media optimization, determination of culture conditions, process conditions, and/or purification procedures.

[00015] Methods disclosed herein can also be utilized to monitor the extent and/or type of high mannose glycans produced in a cell culture, thereby allowing adjustment or possibly termination of the culture in order, for example, to achieve a particular desired high mannose pattern or target or to avoid development of a particular undesired high mannose pattern or target. In some embodiments, the methods can be utilized to compare the extent and/or type of high mannose glycosylation occurring in different cell cultures. In some embodiments, methods may be used to monitor the glycosylation pattern of glycoproteins produced during the course of their production by cells. For example, production of a glycoprotein (e.g., commercial production) may involve steps of (1) culturing cells that produce the glycoprotein, (2) obtaining samples at regular or irregular intervals during the culturing, and (3) analyzing the glycosylation pattern of produced glycoprotein(s) in obtained samples. In some embodiments, such methods may comprise a step of comparing the glycosylation patterns of produced glycoproteins in obtained samples to one another. In some embodiments, such methods may comprise comparing the glycosylation patterns of produced glycoproteins in obtained samples to the glycosylation pattern of a reference sample (such as a control sample or a GMP or pharmaceutical specification or standard).

[00016] The disclosed methods can also be utilized to assess high mannose glycosylation characteristics of cells or cell lines that are being considered for production of a particular desired glycoprotein (for example, even before the cells or cell lines have been engineered to produce the glycoprotein, or to produce the glycoprotein at a commercially relevant level).

Attorney Docket No.: M2050-7059WO/M0074WO

[00017] Methods of the present disclosure can be applied to glycans or glycoproteins obtained from a wide variety of sources including, but not limited to, therapeutic formulations and biological samples. A biological sample may undergo one or more analysis and/or purification steps prior to or after being analyzed according to the present disclosure. Methods of the present disclosure can be utilized to analyze glycans in any of a variety of states including, for instance, free glycans, glycoconjugates (e.g., glycopeptides, glycolipids, proteoglycans, etc.), cell-associated glycans (e.g., nucleus-, cytoplasm-, cell-membrane-associated glycans, etc.); glycans associated with cellular, extracellular, intracellular, and/or subcellular components (e.g., proteins); glycans in extracellular space (e.g., cell culture medium), etc.

[00018] In some embodiments, a desired high mannose glycosylation pattern for a particular target glycoprotein is known, and the methods described herein allow monitoring of culture samples to assess progress of the production along a route known to produce the desired pattern. For example, where the target glycoprotein is a therapeutic glycoprotein, for example having undergone regulatory review in one or more countries, it will often be desirable to monitor cultures to assess the likelihood that they will generate a product with a glycosylation pattern as close to the established glycosylation pattern of the pharmaceutical product as possible, whether or not it is being produced by exactly the same route. In such embodiments, samples of the production culture are typically taken at multiple time points and are compared with an established standard or with a control culture in order to assess relative glycosylation. Among other things, the present disclosure can facilitate real time analysis of high mannose glycosylation in production systems for therapeutic proteins.

[00019] The methods described herein can also be used to assess, control and/or compare the quality of therapeutic products, e.g., to assess the presence, amounts, ratios and/or species of high mannose structures in a therapeutic or otherwise commercially relevant glycoprotein product. For example, the methods can be used in a quality control assay or API or drug product release assay, for example, the methods can include a step of releasing a glycoprotein product for pharmaceutical use if the product meets a control or reference specification for high mannose structures. The reference level can be a specification (e.g., a GMP standard, an FDA label or Physician's Insert) or quality criterion for a pharmaceutical preparation containing the glycoprotein composition. In other embodiments, a comparison is with a historical record of a

Attorney Docket No.: M2050-7059WO/M0074WO

prior or standard batch and/or with a reference sample of glycoprotein. Features of the analysis can be recorded, for example in a quality control record (e.g., a certificate of testing or a certificate of analysis).

[00020] In some embodiments, the reference level or quality criterion is no more than 20%, 15%, 12%, 10% high mannose structures present in a glycoprotein composition, e.g., no more than 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.25%, 0.2%, 0.1% or 0.05%. In one embodiment, the glycoprotein has high mannose structures (e.g., has at least 0.01%, 0.05% or 0.1% high mannose) but has no more than 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.25%, 0.2%, 0.1% or 0.05%, e.g., has between 0.05-20 % high mannose, 0.05-15 % high mannose 0.05-10 % high mannose, between 1-10% high mannose, between 1-5% high mannose. The level of high mannose structures present in a glycoprotein composition can be generally measured as the level of glycans containing high mannose structures relative to total amount of glycans in a sample, such as a glycoprotein preparation.

[00021] In some embodiments, a desired high mannose glycosylation pattern will be enriched for a particular structure. For example, in some embodiments, a desired glycosylation pattern will have lower levels (e.g., less than about 20%, about 15%, about 10%, about 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.2%, 0.1% or less) of high mannose structures, or high levels (e.g., greater than about 5%, 10%, 20%, 25%, 30%, 40%, 50%) of high mannose structures, or specified levels of Man4, Man5, Man 6, Man7, Man8 and/or Man9 (e.g., enrichment of Man5 and/or Man8 relative to other high mannose species or relative to total glycan mass).

Cellular-based analytical methods

[00022] It has been found that multiple cellular pathways interact to determine the pattern of high mannose glycans present on glycoproteins produced from a particular cell. It has been found that the pattern of high mannose glycans on a glycoprotein made by a cell will depend on the balance and patterns of formative vs. consumptive components described herein (e.g., expression of certain genes and availability of certain metabolites described herein) unexpectedly related to biosynthesis of high mannose structures. The patterns of expression or availability of such components in a cell or cell population is indicative or predictive of the pattern of high

Attorney Docket No.: M2050-7059WO/M0074WO

mannose structures produced by the cell or cell population, e.g., is indicative or predictive of the high mannose content of a therapeutic glycoprotein produced by such cell or cell population.

[00023] Accordingly, in another aspect, the invention features a method of evaluating a cell's ability and/or potential to produce high mannose structures. The method includes: providing a cell, and evaluating two or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more) components of the cellular machinery described herein, wherein the result of the evaluation is indicative of the high mannose glycan pattern present in a glycoprotein produced by the cell.

[00024] In one embodiment, the components of the cellular machinery are selected from:

Glycosyltransferases/enzymes

- MGAT1 (GlcNAc T1);
- Alpha mannosidase II, IIx;
- Alpha mannosidase IB;
- Alpha mannosidase IA;
- FucT1-9;
- Glucosidase (e.g., GCS1, GANAB).

precursor levels

- UDP-GlcNAc
- GDP-Man
- UDP/UTP
- GDP/GTP
- Uridine
- Guanosine

precursor biosynthesis or localization or trafficking

Attorney Docket No.: M2050-7059WO/M0074WO

- GNE (glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine)
- Golgi UDP phosphatase
- UDP-GlcNAc transporter
- UAP-1 (UDP-N-acetylhexosamine pyrophosphorylase)
- PGM-3 -phosphoglucomutase 3
- NAGK– N-acetyl-D-glucosamine kinase
- GNPNAT1 – glucosamine-phosphate N-acetyltransferase 1
- UGP-2 - UDP-glucose pyrophosphorylase 2
- UGDH - UDP-glucose 6-dehydrogenaseGALK-1 - Galactokinase-1
- PGM-1 - Phosphoglucomutase-1
- GCK – Glucokinase

Targets to alter the localization or trafficking through the ER and golgi

- Chaperones (BiP, SNARE, cpn's, hsp's)
- EDEM (ER degrading mannosidase-like protein)
- MANEA
- Mannose receptor
- Golgi architecture, structural
- Golgi lipid content (sphingolipid, cholesterol content)
- Trafficking components (A1P1, VIP36)

[00025] In one embodiment, the ratio of expression of MGAT1 to alpha mannosidase IB is evaluated. A low ratio, e.g., less than 1, indicates that the levels of Man5 in a glycoprotein produced by the cell will be elevated relative to the total glycan pool.

Attorney Docket No.: M2050-7059WO/M0074WO

[00026] In one embodiment, the ratio of MGAT1 to alphamannosidase IA is evaluated. A low ratio, e.g., less than 1, indicates that the levels of Man5 in a glycoprotein produced by the cell will be elevated relative to the total glycan pool

[00027] In one embodiment, the ratio of expression of MGAT1 to MGAT2 is evaluated. A low ratio, e.g. less than 1, indicates that the levels of Man5 in a glycoprotein produced by the cell will be elevated relative to the total glycan pool.

[00028] In one embodiment, the ratio of expression of NAGK/GNE and/or NAGK to MGAT2 is evaluated. A low ratio of both, e.g. each less than 1, indicates that the levels of high mannose structures will be elevated relative to the total glycan pool

[00029] In one embodiment, the ratio of expression of MGAT1 to glucosidase is evaluated. A low ratio, e.g. less than 1, indicates that the levels of certain high mannose structures (Man5, Man6, Man7, Man8, and or Man9) will be elevated relative to the total glycan pool.

[00030] In one embodiment, the ratio of expression of Mannosidase IA and IB is evaluated. Differences in ratio of expression of these can affect the composition of high mannose structures (e.g., Man8 and Man9 in particular) present on a glycosylated protein.

[00031] In one embodiment, the ratio of expression of EDEM and mannosidase IA is evaluated. A high ratio, e.g., greater than 1, would indicate a bias toward high mannose in a glycoprotein produced in a cell.

[00032] In one embodiment, the ratio of expression of Mannosidase IIx and MGAT1 is evaluated. A high ratio, e.g., greater than 1, indicates a bias toward lower mannose in a glycoprotein produced in a cell.

[00033] In one embodiment, the ratio of expression of Mannosidase IA and a 1,3 glucosidase (GANAB) is evaluated. A high ratio, e.g., greater than 1, would indicate a bias toward high mannose (e.g., Man9) in a glycoprotein produced in a cell.

Attorney Docket No.: M2050-7059WO/M0074WO

[00034] In one embodiment, the ratio of a fucosyl transferase to mannosidase 1b is evaluated. A low ratio, e.g., less than 1, indicates an enrichment in high mannose, e.g., Man5.

[00035] In one embodiment, the ratio of expression of Mannosidase II to Mannosidase IB is evaluated. A low ratio, e.g., less than 1, indicates enrichment in high mannose, e.g., Man5.

[00036] In one embodiment, the level of VIP36 expression is evaluated. Expression levels of VIP36 influence the mannose content of glycoproteins produced in the cell. In one embodiment, the ratio of expression of VIP36 and Mannosidase IA is evaluated. In one embodiment, the ratio of expression of VIP36 and mannosidase IB is evaluated.

[00037] In one embodiment, the level of UGP-2 is evaluated. Expression levels of UGP-2 influence the mannose content of glycoproteins expressed in the cell. In one embodiment, the ratio of expression of UGP-2 to Mannosidase IB is evaluated. A high ratio (e.g. greater than one) would indicate a higher level of high mannose structures.

[00038] In some embodiments, the method further includes selecting a cell as a host cell for expression of a therapeutic glycoprotein (such as an IgG molecule) based on the result of the method of evaluating a cell's ability and/or potential to produce high mannose structures. For example, in one embodiment the cell is selected as a host cell if the result of the method of evaluating the cell's ability and/or potential to produce high mannose structures indicates that the cell can or will produce a glycoprotein having low levels of high mannose structures (e.g., <20%, <15%, <10%, <9%, <8%, <7%, <6%, <5%, <4%, <3%, <2%, <1%, <0.5% high mannose structures relative to total glycan mass). In another example, in one embodiment the cell is selected as a host cell if the result of the method of evaluating the cell's ability and/or potential to produce high mannose structures indicates that the cell can or will produce a glycoprotein having higher levels of high mannose structures (e.g., >10%, >15%, >20%,) high mannose structures relative to total glycan mass). In another example, in one embodiment the cell is selected as a host cell if the result of the method of evaluating the cell's ability and/or potential to produce high mannose structures indicates that the cell can or will produce a glycoprotein having a predetermined high mannose structure (e.g., a predetermined relative ratio of one high mannose species to another, e.g., relative abundances or ratios of Man4, Man5, Man 6, Man7, Man8 and/or Man9 and isomers thereof; predetermined relative ratios of high mannose to hybrid

Attorney Docket No.: M2050-7059WO/M0074WO

structures; predetermined relative ratios of high mannose to complex structures; predetermined relative ratios of high mannose to fucosylated structures; predetermined abundance of modified high mannose structures (e.g., fucosylated high mannose structures)

[00039] In one embodiment, the method further includes a step of genetically engineering the selected cell to express a therapeutic glycoprotein, e.g., a therapeutic IgG based molecule, e.g., a therapeutic antibody or receptor-Fc fusion protein, e.g., bevacizumab, tositumomab, abciximab, alemtuzumab, acritumomab, cetuximab, adalimumab, ranibizumab, gemtuzumab, efalizumab, infliximab, abciximab, rituximab, basiliximab, eculizumab, palivizumab, omalizumab, daclizumab, ibritumomab tiuxetan, certolizumab pegol, daclizumab, eculizumab, muromonab-CD3, natalizumab, panitumumab, ranibizumab, tositumomab, alefacept, etanercept, abatacept.

[00040] In some embodiment, the method further includes expressing and harvesting the glycoprotein from the genetically engineered cell and evaluating high mannose structures of the produced glycoprotein, e.g., using a method described herein.

Methods to control high mannose structures

[00041] Methods to modulate high mannose structures have been developed. Accordingly, in one aspect, the invention features a method for modulating the glycan structure of a glycoprotein, e.g., a recombinant therapeutic glycoprotein, e.g., modulating the amount or pattern of high mannose structures present in a recombinant therapeutic glycoprotein or otherwise commercially relevant glycoprotein. The method includes (a) providing a host cell genetically engineered to express a subject glycoprotein, and (b) culturing the cell under conditions to express the recombinant protein, wherein the host cell is subject to a manipulation that modulates one or more, e.g., two or more (e.g., 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more) components of the cellular machinery described herein to thereby modulate the high mannose glycan structure of a glycoprotein. In some embodiment, high mannose content is evaluated during culturing and/or at or after harvest of the cells.

Attorney Docket No.: M2050-7059WO/M0074WO

[00042] In one embodiment, the host cell is subject to a manipulation that modulates a glycosyltransferase described herein (e.g., MGAT1). In one embodiment, the glycotransferase expression is decreased but not abolished, e.g., the glycotransferase expression is decreased by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% relative to a parent cell. In some embodiments, this is accomplished by use of: siRNA, antisense RNA, targeted knockout, targeted mutation, modulation of concentration of a divalent cation (e.g., Mn++, Mg+, Co++ or Zn++), modulation of ammonia, elevated pH (e.g., using ulinastatin or chloroquin), chemical inhibitors (such as: Castanospermine, Deoxynojirimycin, Deoxymannojirimycin, Australine, 2,5-Dihydroxymethyl-3,4 Dihydroxypyrrolidine, Kifunensine, Swainsonine, Mannostatin A, 1,4-Dideoxy-1,4-Imino-D-Mannitol); modulation (e.g., addition) of oleic acid, modulation (e.g., addition) of retinoic acid, modulation of transcription factors (e.g., RFX1, Pax-4a, CHOP-10, COUP-TF1, MIF-1, Evi-1, MZF-1, STAT-6, Elk-1, MAZR).

[00043] In one embodiment, the method includes supplementing the cell culture media with a divalent cation, e.g., manganese (Mn++), e.g., MnCl₂ (e.g., from 25-250 uM MnCl₂, from 25-150 uM MnCl₂, 25-100 uM MnCl₂, 25-75 uM MnCl₂, or 25-50 uM MnCl₂). In this embodiment, the method increases the levels of high mannose in a preparation of the glycoprotein produced by the cell, e.g., increases the level of HM5. In one embodiment, the level increases by at least 10%, 20%, 25%, 30%, 40%, 50% or more, relative to the glycoprotein produced by a same host cell cultured in a same media not supplemented with Mn++. In one embodiment, the method also increases the level of afucosylated species of the glycoprotein, e.g., increases the ratio of afucosylated species relative to fucosylated species in a preparation of the glycoprotein produced by the cell. This embodiment may also include a step of measuring the level of high mannose in the glycoprotein, e.g., the total level of high mannose species or the level of one or more of HM4, HM5, HM6, HM7, HM8, HM9, or ratios thereof. This embodiment may also include a step of measuring the level of fucosylation in the glycoprotein, e.g., the total level of afucosylated species or the ratio of afucosylated to fucosylated species in a preparation of the glycoprotein produced by the cell.

[00044] In one embodiment, the method includes obtaining or determining the identity or quantity of a high mannose glycoform in a glycoprotein sample, e.g., by a method described herein, and supplementing the cell culture media with a divalent cation, e.g., manganese (Mn++),

Attorney Docket No.: M2050-7059WO/M0074WO

e.g., MnCl₂ (e.g., from 25-250 uM MnCl₂, from 25-150 uM MnCl₂, 25-100 uM MnCl₂, 25-75 uM MnCl₂, or 25-50 uM MnCl₂), to thereby increase the levels of high mannose in a preparation of the glycoprotein produced by the cell, e.g., increases the level of HM5. In one embodiment, the level increases by at least 10%, 20%, 25%, 30%, 40%, 50% or more, relative to the glycoprotein produced by a same host cell cultured in a same media not supplemented with Mn⁺⁺. In one embodiment, the method includes supplementing the cell culture media with a divalent cation, e.g., manganese (Mn⁺⁺), e.g., MnCl₂ (e.g., from 25-250 uM MnCl₂, from 25-150 uM MnCl₂, 25-100 uM MnCl₂, 25-75 uM MnCl₂, or 25-50 uM MnCl₂), obtaining or determining the identity or quantity of a high mannose glycoform, e.g., by a method described herein, in a glycoprotein sample, comparing the identity or quantity of the high mannose glycoforms to the identity or quantity of a reference sample (e.g., a control sample or a GMP or pharmaceutical specification or standard), and making a decision regarding the glycoprotein, e.g., a decision described herein.

[00045] In one embodiment, the method also increases the level of afucosylated species of the glycoprotein, e.g., increases the ratio of afucosylated species relative to fucosylated species in a preparation of the glycoprotein produced by the cell. This embodiment may also include a step of measuring the level of high mannose in the glycoprotein, e.g., the total level of high mannose species or the level of one or more of HM4, HM5, HM6, HM7, HM8, HM9, or ratios thereof. This embodiment may also include a step of measuring the level of fucosylation in the glycoprotein, e.g., the total level of afucosylated species or the ratio of afucosylated to fucosylated species in a preparation of the glycoprotein produced by the cell.

[00046] In an embodiment the level of high mannose is increased by decreasing the expression of a gene disclosed herein, e.g., MGAT1, wherein expression is decreased by a method or agent which results in a nonlinear relationship between the reduction of expression of the gene, e.g., MGAT1, and increase in high mannose. In an embodiment a plot of the reduction in expression, e.g., of MGAT1, and the increase in high mannose has essentially three phases: a phase where reduction in expression has little or no effect on the level of high mannose (it does not substantially increase high mannose), a phase in which the reduction in the level of expression is essentially linear with the increase in high mannose, and a phase where further reduction in gene expression results in little or no further increase in high mannose. In an

Attorney Docket No.: M2050-7059WO/M0074WO

embodiment, in a method of increasing high mannose, the level of gene expression, e.g., MGAT1 expression, is in the linear phase. In an embodiment the reduction is in the half of the linear phase just before maximal and non-linear phase. In an embodiment the reduction is in the last 25, 10, 5, or 1 % of the linear phase just before maximal and non-linear phase. In an embodiment the level of reduction is no more than 1.5, 2.0 or 4.0 fold greater than the level of reduction of gene expression at the inflection point between the linear phase and the phase where further reductions in gene expression to not give further significant increase in high mannose.

[00047] In one embodiment, the host cell is subject to a delayed or late stage harvest. In some embodiments this includes delaying the harvest until the viability of the cells is less than 40%, 30%, 20% or 10%. In other embodiments this will involve delaying the harvest until the cell number is greater than 6×10^6 , 7×10^6 , 8×10^6 , 10×10^6 , or 15×10^6 cells/ml. In other embodiments a delayed harvest may refer to but would not be limited to harvesting once the levels of media components reach a target level such as less than 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5%, 2%, or 0% of the starting levels. These media components may include, but would not be limited to glucose, galactose, glutamine, or amino acid levels. In other embodiments a delayed harvest may refer to but would not be limited to harvesting once the levels of a cellular biproduct reached a target level such as greater than 2, 4, 6, 8, of 10 fold increase in the starting levels. These biproducts may include but would not be limited to ammonia and lactate. In other embodiments a delayed harvest may refer to delaying the timing of a harvest as compared to an existing feed protocol. This may involve but not be limited to delaying the harvest time for 6, 12, 18, 24, 48, 72, or 96 hrs from the existing process. In other embodiments a delayed harvest may refer to delaying the timing of a harvest until a gas consumption value is met. This may include but not be limited to delaying the harvest time until the level of oxygen consumption is greater than 50, 100, 150, 200, 250, 300, or 350 mmol/L. In other embodiments a delayed harvest may refer to delaying the harvest until a multiple of one, two, three, or four of above parameters are met. In other embodiments a delayed harvest may refer to delaying the harvest until a ratio of two of the above parameters is met. This may include but not be limited to a ratio of Lactate/Glucose that is less than 2, 1, 0.5, 0.25 or 0.1. Alternatively, this may include but not be limited to a ratio of the Oxygen/glucose that is greater than 3, 4, 5, 6, or 7.

Attorney Docket No.: M2050-7059WO/M0074WO

[00048] In one embodiment, the host cell is subject to a delayed feed strategy. In some embodiments a delayed feed strategy may refer but would not be limited to postponing the addition of fed nutrients (e.g. glucose, galactose, amino acids, vitamins, phosphate components etc.) in a fed batch or perfusion culture system until the cell viability is less than 90%, 80%, or 70%, or until the cells reach a particular cell density, such as more than 5×10^6 , 6×10^6 , 7×10^6 , 8×10^6 , 10×10^6 cells/ml. In other embodiments a delayed feed strategy may refer to but would not be limited to the addition of fed nutrients once the levels of media components reach a target level such as less than 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the starting levels. These media components may include, but would not be limited to glucose, galactose, glutamine, or amino acid levels. In other embodiments a delayed feed strategy may refer to but would not be limited to the addition of fed nutrients once the levels of cellular biproduct reach a target level such as greater than 2, 4, 6, 8, or 10 fold increase in the starting levels. These biproducts may include but would not be limited to ammonia and lactate. In other embodiments a delayed feed strategy may refer to delaying the start of timing of a feed strategy as compared to an existing feed protocol. This may involve but not be limited to delaying the initial start time of feed for 6, 12, 18, 24, 48, 72, or 96 hrs from the start of feed in an existing process. In other embodiments a delayed feed strategy may refer to delaying the timing of the subsequent feeds as compared to an existing feed protocol. This may involve but not be limited to delaying each subsequent feed time 6, 12, 18, 24, 48, 72, or 96 hrs from the prior feed point. In other embodiments a delayed feed strategy may refer to delaying the timing of a feed until a gas consumption value is met. This may include but not be limited to delaying the feed until the level of oxygen consumption is greater than 10, 25, 50, 100, 150, 200, 250, 300, or 350 mmol/L. In other embodiments a delayed feed strategy may refer to delaying the timing of feed until a multiple of 2, 3, or 4 of the above parameters are met. In other embodiments a delayed feed may refer to delaying the feed until a ratio of two of the above parameters is met. This may include but not be limited to a ratio of Lactate/Glucose that is less than 2, 1, 0.5, 0.25 or 0.1. Alternatively, this may include but not be limited to a ratio of the Oxygen/glucose that is greater than 3, 4, 5, 6, or 7.

[00049] In another embodiment, the host cell is subject to a manipulation that modulates Golgi architecture, e.g., manipulation (e.g., addition to cell culture) of Brefeldin A, Mycophenolic acid, Destruxin B, Concanamycin B, Leucinostatin A, Efrapeptins.

Attorney Docket No.: M2050-7059WO/M0074WO

[00050] In another embodiment, the host cell is subject to a manipulation that modulates Golgi trafficking (e.g., a modulation (e.g., addition to cell culture) of components that affect budding of one Golgi compartment to another). These include Brefeldin A, Mycophenolic acid, Destruxin B, Concanamycin B, Leucinostatin A, Efrapeptins.

[00051] In another embodiment, the host cell is subject to a manipulation that modulates metabolite or precursor levels, e.g., modulation (e.g., addition to cell culture) of Galactose, 3'F UMP, UDP dialdehyde, UDP, UTP, UDP N-acetylmuramic acid, 5'aminoxy-uridine, 5'-Aminooxy-Glycyl-uridine, ManNAc. Such agents can be naturally occurring or non-naturally occurring derivatives. These may also include targeted manipulation of levels or activities of enzymes involved in the biosynthesis of the metabolites or precursors. These may include but should not be limited to those described above (e.g. GNE, UAP-1, PGM-3, NAGK, GNPAT1, UGP-2, UGDH, GALK-1, PGM-1, GCK, Golgi UDP phosphatase, UDP-GlcNAc transporter). Mechanisms to manipulate enzyme levels include, targeted mutagenesis, siRNA, antisense RNA, targeted knockouts, and structural natural and nonnatural analogs.

[00052] In another embodiment, the host cell is subject to a manipulation that modulates the lipid content of the Golgi such as the addition of inhibitors or sphingolipid biosynthesis (e.g. fumonisin B1, fumonisin B2, L-cycloserine, DL-PDMP, DL-PPMP, DL-threo-dihydroshingpsine, Myriocin, L-erythro MAPP, 3-O-methylsphingomylin, N-butyldeoxynojirimycin, or Oleylethanolamide). In another embodiment the host cell is subjected to manipulation that modulates the levels of cholesterol such as the addition of an inhibitor of cholesterol biosynthesis (such as isopentenyl pyrophosphate, ezetimibe, simvastatin, inhibitors of HMG-CoA reductase) or the addition of a cholesterol sequestering agent such as Methyl- β -cyclodextrin.

[00053] In another embodiment the host cell is subjected to manipulation of levels of enzymes involved in the biosynthesis of the lipid. These enzymes can be found as described in *Molecular Biology of the Cell*, Alberts, Bray, Lewis, Raff, Robers, and Watson eds (1994). Mechanisms to manipulate enzyme levels include targeted mutagenesis, siRNA, antisense RNA, targeted knockouts, and structural and nonnatural analogs.

Attorney Docket No.: M2050-7059WO/M0074WO

[00054] In another embodiment, the host cell is subject to a manipulation that modulates the binding affinity of L-type lectins present in the ER or Golgi (e.g., VIPL VIP36) for high mannose intermediates in the glycosylation pathway through changes in intracompartimental pH (e.g., using ulinastatin or chloroquine)

[00055] In another embodiment, the host cell is subject to manipulation that modulates “quality control” components involved in glycosylation and protein folding such as EDEM, MANEA, GCS1.

[00056] In another embodiment, the host cell is subject to manipulation that modulates the intracellular distribution (e.g., the localization of these enzymes preferentially to either the ER or Golgi) of mannosidase 1a and 1b.

[00057] In another embodiment, the host cell is subjected to manipulation that modulates the expression level of the protein that contains the high mannose structure (e.g. an antibody). This may be through addition of agents to acetylate chromatin (e.g. butyrate). Additionally this may be by increasing the number of genetic copies of the gene expressing the protein (e.g. antibody, e.g. through dhfr amplification, through targeted insertion, through viral insertion, through promoter sequences). In other embodiments this may be through increasing the rate of transcription or translation of the protein (e.g. antibody, e.g. through enhancer sequences, through codon optimization, promoter sequences)

[00058] In one embodiment, the method includes a step of measuring high mannose content or patterns at one or more of: before and/or after the manipulation; during culturing of the cells, after harvest of the cells, after purification of the glycoprotein.

[00059] In certain embodiment, the method includes a step of determining a desired or target level of high mannose content before manipulation. The target or desired level may be, e.g., >20%, >30%, >40%. The target or desired level may be, e.g., <20%, <15%, <10%, <8%, <7%, <6%, <5%, <4%, <3%, <2%, <1%, <0.5%. The target or desired level may be, e.g., enriched or increased levels of Man4, Man5, Man6, Man7, Man8, or Man9. This determination may include but not be limited to measuring the levels of high mannose on a reference

Attorney Docket No.: M2050-7059WO/M0074WO

compound, or be determined based on a desired biology, structural consideration, or by consultation of literature.

[00060] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

BRIEF DESCRIPTION OF THE FIGURES

[00061] **Figure 1** is a cartoon of the pathway for biosynthesis of high mannose and complex glycans. The monosaccharides that compose the N-glycan are illustrated as the following; Fucose (light grey triangle), GlcNAc (black square), Mannose (dark grey circle), and Galactose (light grey circle). The structures that represent the high mannose species are indicated as HM9, HM8, etc.

[00062] **Figure 2** is a set of LC profiles of glycans harvested from a wild-type cell line (CHO) and a Lec1 mutant (MGAT1 null) cell line.

[00063] **Figure 3** is a set of plots reflecting glycan levels modeled to reflect varying levels of MGAT1. Each plot refers to the level of the indicated glycan (% of starting) based on the level of MGAT1 expression (% of starting). These illustrate that an elevation of High mannose structures does not require complete abolition of the MGAT1 transferase

[00064] **Figure 4** is a set of plots representing a linear analysis of the expression of the gene UGP-2 in a cell population as it correlates to Man5 content on a glycoprotein produced by the cell. Each dot on this plot indicates a particular clone of one of four listed transformed cell lines.

[00065] **Figure 5** is a plot of increasing levels of MnCl₂ vs levels (% of total glycans) of Man5. The data represent duplicate determinants.

DETAILED DESCRIPTION

Definitions

Attorney Docket No.: M2050-7059WO/M0074WO

[00066] "High Mannose" as used herein refers to one or a multiple of N-glycan structures including HM4, HM5, HM6, HM7, HM8, and HM9 containing 3, 4, 5, 6, 7, 8, or 9 mannose residues respectively. Alternatively these may be called Man4, Man5, Man6, Man7, Man8, Man9. These structures are illustrated in figure 1 as indicated.

[00067] A "preparation of cells", as used herein, refers to an *in vitro* preparation of cells. In the case of cells from multicellular organisms (e.g., plants and animals), a purified preparation of cells is a subset of cells obtained from the organism, not the entire intact organism. In the case of unicellular microorganisms (e.g., cultured cells and microbial cells), it consists of a preparation of at least 10% and more preferably 50% of the subject cells.

[00068] The term "genetically engineered," as used herein in reference to cells, is meant to encompass cells that express a particular gene product following introduction of a heterologous DNA molecule into the cell. The heterologous DNA can be a sequence encoding the gene product and/or including regulatory elements that control expression of a coding sequence (e.g., of an endogenous sequence) for the gene product. The DNA molecule may be introduced by gene targeting or homologous recombination, i.e., introduction of the DNA molecule at a particular genomic site.

[00069] The disclosure of WO 2008/128227 is incorporated herein in its entirety. Various aspects of the invention are described in further detail below.

Host cells/Genetically Engineered Cells

[00070] A host cell used to produce a glycoprotein described herein can be any cell containing cellular machinery to produce high mannose structures. For example, insect cells, plant cells, yeast, or mammalian cells (such as murine, human or CHO cells). CHO cells useful as host cells include cells of any strain of CHO, including CHO K1 (ATCC CCL-61), CHO pro3-, CHO DG44, CHO-S, CHO P12 or the dhfr- CHO cell line DUK-BII (Chassin et al., PNAS 77, 1980, 4216-4220). Murine cells useful as host cells include strains of NS0 or other hybridoma cell types, or similar rodent cells of BHK. Human cells useful as host cells include strains of PerC6, hybridoma cells, or retinal cells to name a few.

Attorney Docket No.: M2050-7059WO/M0074WO

[00071] Suitable mammalian cells include any normal mortal or normal or abnormal immortal animal or human cell, including: monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293) (Graham et al., *J. Gen. Virol.* 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese Hamster Ovary (CHO), e.g., DG44, DUKX-V11, GS-CHO (ATCC CCL 61, CRL 9096, CRL 1793 and CRL 9618); mouse sertoli cells (TM4, Mather, *Biol. Reprod.* 23:243 251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African green monkey kidney cells (VERO-76, ATCC CRL 1587); human cervical carcinoma cells (HeLa, ATCC CCL 2); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse melanoma cells (NSO); mouse mammary tumor (MMT 060562, ATCC CCL51), TRI cells (Mather, et al., *Annals N.Y. Acad. Sci.* 383:44 46 (1982)); canine kidney cells (MDCK) (ATCC CCL 34 and CRL 6253), HEK 293 (ATCC CRL 1573), WI-38 cells (ATCC CCL 75) (ATCC: American Type Culture Collection, Rockville, Md.), MCF-7 cells, MDA-MB-438 cells, U87 cells, A127 cells, HL60 cells, A549 cells, SP10 cells, DOX cells, SHSY5Y cells, Jurkat cells, BCP-1 cells, GH3 cells, 9L cells, MC3T3 cells, C3H-10T1/2 cells, NIH-3T3 cells and C6/36 cells. The use of mammalian tissue cell culture to express polypeptides is discussed generally in Winnacker, *FROM GENES TO CLONES* (VCH Publishers, N.Y., N.Y., 1987).

[00072] Exemplary plant cells include, for example, *Arabidopsis thaliana*, rape seed, corn, wheat, rice, tobacco etc.) (Staub, et al. 2000 *Nature Biotechnology* 1(3): 333-338 and McGarvey, P. B., et al. 1995 *Bio-Technology* 13(13): 1484-1487; Bardor, M., et al. 1999 *Trends in Plant Science* 4(9): 376-380). Exemplary insect cells (for example, *Spodoptera frugiperda* Sf9, Sf21, *Trichoplusia ni*, etc. Exemplary bacteria cells include *Escherichia coli*. Various yeasts and fungi such as *Pichiapastoris*, *Pichia methanolica*, *Hansenula polymorpha*, and *Saccharomyces cerevisiae* can also be selected.

[00073] Other suitable host cells are known to those skilled in the art.

[00074] Methods to make and use host cells of the invention, and to make therapeutic glycoproteins in such host cells are known in the art. For example, methods are provided in Current Protocols in Cell Biology (2007, John Wiley and Sons, Inc., Print ISSN: 1934-2500); Current Protocols in Protein Science (2007, John Wiley and Sons, Inc., Print ISSN: 1934-3655);

Attorney Docket No.: M2050-7059WO/M0074WO

Wurm, *Production of recombinant protein therapeutics in cultivated mammalian cells* (2004) *Nature Biotech.* 22:1393-1398; *Therapeutic Proteins: Methods and Protocols*, Smales and James, eds. (2005, Humana Press, ISBN-10: 1588293904).

Methods to Detect gene Expression or Activity

[00075] Nucleic acid based-detection methods encompass hybridization or amplification assays that include, but are not limited to, Southern or Northern analyses, polymerase chain reaction analyses (e.g., quantitative PCR), SAGE analyses, probe arrays or oligonucleotide arrays. Probes useful in such methods are routinely selected from known gene sequences. In some cases, cellular material from one species, (e.g., one rodent species such as Chinese Hamster) may be evaluated using probes identified from ortholog gene sequences (e.g., rat or mice-derived seqeunces) found in the art.

[00076] Antibody-based techniques for detection of proteins include enzyme linked immunosorbent assays (ELISAs), immunoprecipitations, immunofluorescence, enzyme immunoassay (EIA), radioimmunoassay (RIA), Western blot analysis, surface plasmon resonance. Other methods may include the detection of peptides or fragments thereof using mass spectrometric-based methods, including, but not limited to LC-MS, MS/MS, MS/MS/MS, MALDI-MS, multiple reaction monitoring (MRM).

[00077] In one embodiment, detection methods described herein are part of determining a gene expression profile of the sample, wherein the profile includes a value representing the level of a gene's expression, among at least one other value for expression of at least one other gene. The method can further include comparing the value or the profile (i.e., multiple values) to a reference value or reference profile. The gene expression profile of the sample can be obtained by any of the methods described herein (e.g., by providing a nucleic acid from the sample and contacting the nucleic acid to an array). The method can be used to evaluate or screen CHO cells.

[00078] In another aspect, the invention features a computer medium having a plurality of digitally encoded data records. Each data record includes a value representing the level of expression of a gene in a sample, and a descriptor of the sample. The descriptor of the sample can be an identifier of the sample, e.g., the cell type from which the sample was derived (e.g., a

Attorney Docket No.: M2050-7059WO/M0074WO

CHO cell strain), or a cell culture condition under which the cell that is the source of the sample was cultured. In one embodiment, the data record further includes values representing the level of expression of genes other than Ggtal1 (e.g., other genes associated with glycan synthesis, or other genes on an array). The data record can be structured as a table, e.g., a table that is part of a database such as a relational database (e.g., a SQL database of the Oracle or Sybase database environments).

Methods of Modulating Gene Expression

[00079] In certain methods of the invention, gene expression is modulated, e.g., increased or reduced. Such methods may include reducing (knocking-down) expression or abolishing (knocking out) expression of a subject gene. Methods of making and using antisense molecules to modulate biological activities are known in the art, see for example: Pan and Clawson, Antisense applications for biological control (2006) *J. Cell Biochem.* 98(1):14-35; Sioud and Iversen, Ribozymes, DNAzymes and small interfering RNAs as therapeutics (2005) *Curr Drug Targets* 6(6):647-53; Bhindi et al., Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies (2007) *Am J Pathol.* 171(4):1079-88. Methods of making gene knockouts are known in the art, e.g., see Kuhn and Wurst (Eds.) Gene Knockout Protocols (Methods in Molecular Biology) Humana Pres (March 27, 2009).

[00080] In some embodiments, a cell can be selected which has been genetically engineered for permanent or regulated inactivation of a gene encoding a protein involved with the synthesis of a particular glycan as described herein. For example, genes encoding an enzyme such as the enzymes described herein can be inactivated. Permanent or regulated inactivation of gene expression can be achieved by targeting to a gene locus with a transfected plasmid DNA construct or a synthetic oligonucleotide. The plasmid construct or oligonucleotide can be designed to several forms. These include the following: 1) insertion of selectable marker genes or other sequences within an exon of the gene being inactivated; 2) insertion of exogenous sequences in regulatory regions of non-coding sequence; 3) deletion or replacement of regulatory and/or coding sequences; and, 4) alteration of a protein coding sequence by site specific mutagenesis.

Attorney Docket No.: M2050-7059WO/M0074WO

[00081] In the case of insertion of a selectable marker gene into coding sequence, it is possible to create an in-frame fusion of an endogenous exon of the gene with the exon engineered to contain, for example, a selectable marker gene. In this way following successful targeting, the endogenous gene expresses a fusion mRNA (nucleic acid sequence plus selectable marker sequence). Moreover, the fusion mRNA would be unable to produce a functional translation product.

[00082] In the case of insertion of DNA sequences into regulatory regions, the transcription of a gene can be silenced by disrupting the endogenous promoter region or any other regions in the 5' untranslated region (5' UTR) that is needed for transcription. Such regions include, for example, translational control regions and splice donors of introns. Secondly, a new regulatory sequence can be inserted upstream of the gene that would render the gene subject to the control of extracellular factors. It would thus be possible to down-regulate or extinguish gene expression as desired for glycoprotein production. Moreover, a sequence which includes a selectable marker and a promoter can be used to disrupt expression of the endogenous sequence. Finally, all or part of the endogenous gene could be deleted by appropriate design of targeting substrates.

[00083] Other methods of affecting gene expression, e.g., increasing or reducing gene expression, may involve addition of agents, e.g., addition of specified agents to culture media, e.g., as described herein.

Biology of High Mannose Structures

[00084] The presence of mannose containing glycans on proteins is known to have an effect on the interaction of these proteins with several receptors and binding partners through which the function, distribution, and stability of these mannose-containing proteins are influenced. Such binding partners includes Fc receptors, FcRn, mannose binding lectins (MBL), C1q, mannose receptor, DC and L-sign, and receptors on specific cells (see, e.g., Li et al., (2009) Curr Opin Biotechnol. 20, 678-684). Thus, methods described herein are useful to evaluate or modulate targeting of glycoproteins to specific tissues (e.g., bone marrow, mammary epithelia, intestinal epithelia), to specific cell types (e.g., dendritic cells, macrophages) or specific compartments (e.g., lysosome). The methods described herein are also useful to evaluate or

Attorney Docket No.: M2050-7059WO/M0074WO

modulate biological activity through receptor binding (e.g., Fc receptors), serum half lives/clearance (e.g., through binding to the mannose receptor, FcRn) and adsorption.

[00085] The methods described herein are also useful to evaluate or modulate other biological activities, including: antibody deposition and aggregation. The glycan structure on the Fc portion of an antibody change the 3 dimensional structure of the antibody. Alterations in antibody structure are known to have the potential to lead to antibody aggregation and deposition. The methods used herein would be useful to generate antibodies with targeted levels of high mannose so as to decrease antibody sera deposition, complex formation and aggregation. Similarly, these structural changes can be utilized to increase or decrease immunogenicity of an antibody.

[00086] In some embodiments, the antibody molecules may also contain glycosylation on the Fab portion of the molecule. In these instances, in addition to those biology described above, the presence of a high mannose structure may also alter the affinity for the epitopes, or the ability for the antibody to form cross linked complexes on the cell surface. The methods described herein would be useful to generate antibodies with altered levels of high mannose structures so as to “dial” in desired affinity, as well as achieve a desired level of receptor cross linking so as to decrease off target effects and increase the therapeutic window. In addition design of high mannose containing peptides and polypeptides may inhibit protein degradation through ubiquitin ligase mediated pathway.

[00087] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

[00088] This invention is further illustrated by the following examples that should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

EXAMPLES

Example 1: High Throughput Analysis of High Mannose Protein Glycoforms

Attorney Docket No.: M2050-7059WO/M0074WO

[00089] One of the major challenges in characterizing low abundance glycoforms in a mixture is the presence of higher abundance glycoforms as well as the diverse array of glycoforms in the mixture. The analysis of low abundance glycoforms typically involves the release of the glycans from the protein either by enzymatic (PNGAse-F or Endo-H) or chemical treatment (i.e. hydrazinolysis). The released glycans are then purified and subsequently analyzed without further derivatization or after the labeling with different chromophores/fluorophores. However, the laborious sample preparation steps involved in this process as well as the high amounts of material needed for these analyses hampers the ability to use these types of methods in a high throughput setting.

[00090] The method described here is useful to analyze high mannose containing glycoforms, and in particular high mannose glycoforms present in low abundance (e.g., <10%, <5%, <4%, <3%, <2%, <1%, <0.05%).

[00091] Starting with a glycoprotein-containing sample such as an antibody sample (e.g., from either media, or a protein preparation) optionally perform a buffer exchange to buffer compatible with enzymatic digest of step #2 and/or mass spectrometry analysis of step #3. This step is optional depending on the sample formulation or the chromatographic method of step 3. Treat the glycoprotein sample with an enzyme that cleaves complex fucosylated glycans from the glycoprotein in the sample (e.g., Endoglycosidase F3 (<http://glycotools.qa-bio.com/s.nl/it.A/id.96/f>)). This step unexpectedly reveals low abundance glycoforms such as high mannose species, in the remaining sample. In the next step, optionally reduce and alkylate the sample and/or perform a buffer exchange to buffer compatible with MS. In a next step, analyze the enzymatically treated sample by a reverse phase LC-MS or targeted reverse phase-LC-MS analysis to identify high mannose-containing glycoforms. Other types of column chemistries can also be employed. Knowing the theoretical masses of the high mannose-containing glycoforms, a targeted MS experiment can be established to only monitor selected set of m/z signatures corresponding to these species. The analysis can be repeated with multiple samples in a comparative analysis setting.

Attorney Docket No.: M2050-7059WO/M0074WO

[00092] The method described above provides an excellent balance between throughput, resolution and sensitivity making it particularly suitable for the analysis of low abundance glycoforms containing high mannose in a high throughput setting.

Example 2: Effect of MGAT1 levels on Man5 structures

[00093] Wild type CHO (WT) and Lec1 (MGAT1 null) cell lines were stably transformed to express an IgG model fusion protein. The recombinant product was harvested from the cells, and N-glycans analyzed by Amide LC/MS. LC data from WT (top) and MGAT1 deficient (bottom) CHO cells with representative glycans identified with relative percentage is shown in Figure 2. As can be seen in Figure 2, the glycoprotein produced from the Lec1 mutant lacks Man5 structures.

[00094] However, it has been found that complete inhibition of MGAT1 is not necessary to produce this effect. Figure 3 a set of plots reflecting glycan levels modeled to reflect varying levels of MGAT1. Each plot refers to the level of the indicated glycan (% of starting) based on the level of MGAT1 expression (% of starting). These illustrate that an elevation of high mannose structures does not require complete abolition or depletion of the MGAT1 transferase.

Example 3: Identification of non-linear correlations related to high mannose content

[00095] This example illustrates the identification of unexpected, non-linear correlations between glycosylation regulators and high mannose content.

[00096] Stably transformed clones expressing an IgG fusion model protein were generated from each of the cell lines CHOK1, CHOS, DG44 and Dhfr-. The IgG product was isolated from each clone and the glycans characterized by 2D LC/MS. The level of Man5 was determined as a percentage of total glycans. Concurrently, mRNA was extracted from each clone and the levels of various enzymes involved in disparate aspects of glycobuilding were characterized. Such enzymes include glycosyltransferases, transporters, metabolic enzymes, and others involved in the biosynthesis of glycans. These data were subjected to linear analysis to identify relations between particular biosynthetic steps and Man5 content. Figure 4A shows the level of gene expression of UGP-2 as it unexpectedly shows a linear correlation to Man5 content

Attorney Docket No.: M2050-7059WO/M0074WO

on a glycoprotein produced by the cell. While not bound by theory, Figure 4B illustrates how this gene can, in retrospect, be correlated to metabolites involved in Man5 biosynthesis.

Example 4: Man5 levels affected by high concentrations of divalent cations

[00097] This example illustrates the inhibitory affect of elevated levels of divalent cations on glycoenzyme activity.

[00098] CHO cells expressing an IgG fusion model protein were cultured in the presence of increasing levels of MnCl₂. Product was harvested from these cells after 5 days, purified, and subjected to N-glycan analysis by normal phase HPLC. The levels (% of total glyans) of Man5 were quantified and are shown in Figure 5. As can be seen, as the levels of Mn in the media are elevated there is a concommittant increase in high mannose content. While not bound by theory, this may be driven primarily by Mn cofactor activity on transferases.

Extensions and Alternatives

[00099] All literature and similar material cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety. In the event that one or more of the incorporated literature and similar materials differs from or contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way. While the methods have been described in conjunction with various embodiments and examples, it is not intended that the methods be limited to such embodiments or examples. On the contrary, the methods encompass various alternatives, modifications, and equivalents, as will be appreciated by those of skill in the art.

We claim:

1. A method to identify and/or quantify high mannose glycoforms in a glycoprotein sample, the method comprising: (a) providing a glycoprotein mixture-containing sample; (b) optionally performing a buffer exchange to buffer compatible with enzymatic digest and/or mass spectrometry (MS) analysis, (c) removing higher abundance glycans from the glycoprotein sample, (d) optionally reducing and alkylating the sample and/or performing a buffer exchange to buffer compatible with mass spectrometry, and (e) quantifying a high mannose-containing glycoform in the treated sample.
2. The method of claim 1, wherein step (c) comprises treating the glycoprotein sample with an enzyme that cleaves complex fucosylated glycans from the glycoprotein.
3. The method of claim 1, wherein step (c) comprises treating the glycoprotein sample with Endoglycosidase F3.
4. The method of claim 1, wherein step (e) comprises performing capillary electrophoresis (CE); reverse phase LC-MS or targeted reverse phase-LC-MS on the treated sample.
5. The method of claim 1, further comprising determining one or more of:
 - (i) the amount of high mannose glycoforms in the glycoprotein sample relative to total glycoforms;
 - (ii) one or more relative ratios of two high mannose species selected from Man4, Man5, Man6, Man7, Man8 and Man9, in the glycoprotein sample;
 - (iii) the relative ratio of high mannose to hybrid structures in the glycoprotein sample,
 - (iv) the relative ratio of high mannose to complex structures in the glycoprotein sample,
 - (v) the relative ratio of high mannose to fucosylated structures in the glycoprotein sample;
 - (vi) the presence or abundance of modified high mannose structures (e.g., the presence or abundance of fucosylated high mannose structures) in the glycoprotein sample.

Attorney Docket No.: M2050-7059WO/M0074WO

6. The method of claim 1, wherein the method separately identifies and/or quantifies at least two individual glycoforms in the glycoprotein sample.
7. The method of claim 1, wherein the glycoprotein sample is an antibody preparation or an receptor-Fc fusion preparation.
8. The method of claim 7, wherein the antibody preparation is a pharmaceutical preparation produced from a mammalian cell culture.
9. The method of claim 1, wherein the method is performed under GMP conditions.
10. The method of claim 1, further comprising comparing the quantified amount of high mannose glycoforms to a reference level or quality criterion.
20. A method for identifying and/or quantifying high mannose and/or hybrid structures in a glycan or glycoprotein preparation, the method comprising: (a) providing a glycan or glycoprotein mixture, (b) treating the glycan mixture or glycoprotein mixture with an enzyme that cleaves the exposed terminal mannosidase residues at the non-reducing end of a glycoform, and (c) quantifying the cleaved terminal mannose residues, to thereby analyze high mannose and/or hybrid structures in a glycan or glycoprotein preparation.
21. The method of claim 20, wherein the quantifying step includes performing quantitative monosaccharide analysis by HPLC or GC-MS.
22. The method of claim 20, wherein the cleaved terminal mannoses are quantified relative to total glycan mass.
23. The method of claim 20, wherein the glycoprotein preparation is an antibody preparation or an receptor-Fc fusion preparation.

Attorney Docket No.: M2050-7059WO/M0074WO

24. The method of claim 23, wherein the antibody preparation is a pharmaceutical preparation produced from a mammalian cell culture.
25. The method of claim 20, wherein the method is performed under GMP conditions.
26. The method of claim 20, further comprising comparing the quantified amount of high mannose glycoforms to a reference level or quality criterion.
30. A method of evaluating a cell's ability and/or potential to produce high mannose structures, the method comprising:
 - (a) providing a cell, and
 - (b) evaluating two or more components of the cellular machinery selected from the group consisting of: MGAT1 (GlcNAc T1); Alpha mannosidase II, Alpha mannosidase IIx; Alpha mannosidase IB; Alpha mannosidase IA; FucT1-9; Glucosidase GCS1; GANAB; levels of UDP-GlcNAc, GDP-Man; UDP/UTP; GDP/GTP; Uridine; Guanosine; GNE (glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine); Golgi UDP phosphatases; UDP-GlcNAc transporter; UAP-1 (UDP-N-acetylhexosamine pyrophosphorylase); PGM-3 - phosphoglucomutase 3; NAGK - N-acetyl-D-glucosamine kinase; GNPNAT1 - glucosamine-phosphate N-acetyltransferase 1; UGP-2 - UDP-glucose pyrophosphorylase 2; UGDH - UDP-glucose 6-dehydrogenase; GALK-1 - Galactokinase-1; PGM-1 - Phosphoglucomutase-1; GCK - Glucokinase; a Chaperones (BiP, SNARE, cpn's, hsp's); EDEM (ER degrading mannosidase-like protein); MANEA; Mannose receptor; Golgi architecture; Golgi lipid content (sphingolipid, cholesterol content); A1P1, VIP36,
wherein the result of the evaluation is indicative of the high mannose glycan content or pattern present in a glycoprotein produced by the cell.
31. The method of claim 30, wherein the cell is a mammalian cell.
32. The method of claim 30, wherein the ratio of expression of MGAT1 to alpha mannosidase IB is evaluated.

Attorney Docket No.: M2050-7059WO/M0074WO

33. The method of claim 30, wherein the ratio of MGAT1 to alpha mannosidase IA is evaluated.

34. The method of claim 30, wherein the ratio of expression of MGAT1 to MGAT2 is evaluated.

35. The method of claim 30, wherein the ratio of expression of NAGK/GNE and/or NAGK to MGAT2 is evaluated.

36. The method of claim 30, wherein the ratio of expression of MGAT1 to glucosidase is evaluated.

37. The method of claim 30, wherein the ratio of expression of Mannosidase IA and IB is evaluated.

38. The method of claim 30, wherein the ratio of expression of EDEM and mannosidase IA is evaluated.

39. The method of claim 30, wherein the ratio of expression of Mannosidase IIx and MGAT1 is evaluated.

40. The method of claim 30, wherein the ratio of expression of Mannosidase IA and a 1,3 glucosidase (GANAB) is evaluated.

41. The method of claim 30, wherein the ratio of a fucosyl transferase to mannosidase IB is evaluated.

42. The method of claim 30, wherein the ratio of expression of Mannosidase II to Mannosidase IB is evaluated.

43. The method of claim 30, wherein the level of VIP36 expression is evaluated.

Attorney Docket No.: M2050-7059WO/M0074WO

44. The method of claim 30, wherein the ratio of expression of VIP36 and Mannosidase IA is evaluated.

45. The method of claim 30, wherein UGP-2 expression or the ratio of expression of UGP-2 to Mannosidase IB is evaluated.

46. The method of claim 30, wherein the levels of at least two precursor sugar nucleotides are evaluated.

47. The method of claim 30 wherein the levels of at least one sugar nucleotide and one nucleotide are evaluated.

48. The method of any one of claims 30-47, wherein the method further includes selecting a cell as a host cell for expression of a therapeutic glycoprotein based on the result of the evaluating step.

49. The method of claim 48, wherein a cell is selected as a host cell if the result of the evaluating step indicates that the cell can or will produce a glycoprotein having <20% high mannose structures.

50. The method of claim 48, wherein a cell is selected as a host cell if the result of the evaluating step indicates that the cell can or will produce a glycoprotein having >10% high mannose structures.

51. The method of claim 48, wherein a cell is selected as a host cell if the result of the evaluating step indicates that the cell can or will produce a glycoprotein having a pre-determined high mannose structure.

52. The method of claim 51, wherein the pre-determined high mannose structure is selected from: a predetermined relative ratio of one high mannose species (Man4, Man5, Man 6, Man7,

Attorney Docket No.: M2050-7059WO/M0074WO

Man8 and/or Man9) to another, a predetermined relative ratio of high mannose to hybrid structures; a predetermined relative ratio of high mannose to complex structures; a predetermined relative ratio of high mannose to fucosylated structures; a predetermined abundance of modified high mannose structures (e.g., fucosylated high mannose structures).

53. The method of claim 48, wherein the method further comprises a step of genetically engineering the selected cell to express a therapeutic glycoprotein.

54. The method of claim 53, wherein the therapeutic glycoprotein is an IgG based molecule selected from: bevacizumab, tositumomab, abciximab, alemtuzumab, acritumomab, cetuximab, adalimumab, ranibizumab, gemtuzumab, efalizumab, infliximab, abciximab, rituximab, basiliximab, eculizumab, palivizumab, omalizumab, daclizumab, ibritumomab tiuxetan, certolizumab pegol, daclizumab, eculizumab, muromonab-CD3, natalizumab, panitumumab, ranibizumab, tositumomab, alefacept, etanercept, and abatacept.

55. The method of claim 54, further comprising expressing and harvesting the glycoprotein from the genetically engineered cell and evaluating high mannose structures of the produced glycoprotein.

56. A method for modulating the amount or pattern of high mannose structures of a recombinant glycoprotein, the method comprising: (a) providing a host cell genetically engineered to express a subject glycoprotein, and (b) culturing the cell under conditions to express the recombinant protein, wherein the host cell is subject to a manipulation that modulates one or more components of the cellular machinery described herein.

57. The method of claim 56, wherein the host cell is subject to a manipulation that modulates a glycotransferase described herein (e.g., MGAT1).

58. The method of claim 56, wherein MGAT1 expression is decreased by at least 10%, but is not abolished.

Attorney Docket No.: M2050-7059WO/M0074WO

59. The method of claim 56, wherein gene expression of a glycotransferase described herein is decreased by use of: siRNA, targeted knockout, targeted mutation, modulation of concentration of a divalent cation (e.g., Mn⁺⁺, Mg⁺, Co⁺⁺ or Zn⁺⁺), modulation of ammonia, elevated pH (e.g., using ulinastatin or chloroquin), chemical inhibitors (such as: Castanospermine, Deoxynojirimycin, Deoxymannojirimycin, Australine, 2,5-Dihydroxymethyl-3,4 Dihydroxypyrrolidine, Kifunensine, Swainsonine, Mannostatin A, 1,4-Dideoxy-1,4-Imino-D-Mannitol); modulation (e.g., addition) of oleic acid, modulation (e.g., addition) of retinoic acid, or modulation of transcription factors (e.g., RFX1, Pax-4a, CHOP-10, COUP-TF1, MIF-1, Evi-1, MZF-1, STAT-6, Elk-1, MAZR).

60. The method of claim 56, wherein the host cell is subject to a delayed or late stage harvest.

61. The method of claim 56, wherein the host cell is subject to a delayed feed strategy.

62. The method of claim 56, wherein the host cell is subject to a manipulation that modulates Golgi architecture.

63. The method of claim 56, wherein the host cell is subject to a manipulation that modulates Golgi trafficking.

64. The method of claim 56, wherein the host cell is subject to a manipulation that modulates metabolite levels described herein.

65. The method of claim 56, wherein the host cell is subject to a manipulation that modulates the lipid content of the Golgi.

66. The method of claim 56, further comprising a step of measuring high mannose content or patterns at one or more of: before and/or after the manipulation; during culturing of the cells, after harvest of the cells, after purification of the glycoprotein.

Attorney Docket No.: M2050-7059WO/M0074WO

67. The method of claim 56, further comprising a step of determining a desired or target level of high mannose content before manipulation.




Fig. 1

2/6




Fig. 2

3/6




Fig. 3

4/6




Fig. 4A

5/6




Fig. 4B

6/6




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/31637

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12Q 1/00; C12P 21/06; H01J 49/00 (2011.01)
 USPC - 435/4; 435/69.1; 250/288

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 USPC: 435/4; 435/69.1; 250/288

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 USPC: 435/69.3, 435/468, 435/200, 435/325, 435/68.1; 73/61.52; 530/395, 530/402, 530/303, 530/345, 530/351, 530/388.23; 506/12; 514/11.4, 514/14.6, 514/14.7, 514/4.3, 514/7.7, 514/5.9, 514/9.8, 514/9.9, 1.1, 5.4; 424/208.1, 93.7, 94.64, 85.1, 85.2 (keywords below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PubWEST (PGPB, USPT, USOC, EPAB, JPAB); Google; PubMed; Search terms: high mannose, glycoprotein, HPLC, mass spectrometry, endoglycosidase F3, antibody, Fc, MGAT1, alpha mannosidase IA, alpha mannosidase IB, NAGK, glucosidase, EDEM, mannosidase IIX, GANAB, mannosidase II, VIP36, delayed feed, brefeldin a, hybridoma, production, fumonisin, golgi

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	HOJA-LUKOWICZ et al. High-mannose-type oligosaccharides from human placental arylsulfatase A are core fucosylated as confirmed by MALDI MS. Glycobiology 2000, 10(6):551-557; abstract; Fig. 1, 2; pg 552, para 2, 4; pg 555, para 1, 3, 6-7, 9; pg 556, para 2-4; Table 1	1-2, 5-6, 10 ----- 3-4, 7-9, 20-26, 41
X --- Y	YE et al. N-glycan branching requirement in neuronal and postnatal viability. Glycobiology 2004, 14(6):547-558; Fig. 3; pg 551, para 3	30-31, 34 ----- 32-33, 35-55
X --- Y	KANDA et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 2007, 17(1):104-118; abstract; pg 114, para 2 - pg 115, para 3; Fig. 2; Table II	56-57, 60, 66-67 ----- 7-9, 48-55, 58-59, 61-65
Y	Chen, et al. Independent Lect1A CHO Glycosylation Mutants Arise from Point Mutations in N-Acetylglucosaminyltransferase I That Reduce Affinity for Both Substrates. Molecular Consequences Based on the Crystal Structure of GlcNAc-TI. Biochemistry 2001, 40(30):8765-72; abstract; Tables 1, 2; Fig. 2; pg 8767, para 3, 6	58-59, 64
Y	GATES et al. Glycoprotein Analysis Manual, 1st ed. Sigma-Aldrich, St. Louis, MO 2004, pg 19, 21, 25-28, 36-37, 72; Fig. 1	3-4, 20-26
Y	KAWASHIMA et al. Tyrosine kinase activity of epidermal growth factor receptor is regulated by GM3 binding through carbohydrate to carbohydrate interactions. J. Biol. Chem. 2009, 284(10):6147-6155; abstract	32



Further documents are listed in the continuation of Box C.



* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 August 2011 (22.08.2011)

Date of mailing of the international search report

30 AUG 2011

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/31637

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AKIYAMA et al. Analysis of the role of glycosylation of the human fibronectin receptor. <i>J. Biol. Chem.</i> 1989, 264(30):18011-18018; abstract; pg 18012, para 5	33
Y	BREIDENBACH et al. Targeted metabolic labeling of yeast N-glycans with unnatural sugars. <i>Proc. Natl. Acad. Sci. USA</i> 2 March 2010, 107(9):3988-3993; Fig. 1	35
Y	CHEN et al. T cell receptor signaling co-regulates multiple Golgi genes to enhance N-glycan branching. <i>J. Biol. Chem.</i> 2009, 284(47):32454-32461; Fig. 1A	36-42, 44
Y	HARA-KUGE et al. Vesicular-integral membrane protein, VIP36, recognizes high-mannose type glycans containing alpha1-->2 mannose residues in MDCK cells. <i>Glycobiology</i> 1999, 9(8):833-839; abstract; pg 837, para 2	43-44
Y	CHEN et al. Mammalian Glycosylation: An Overview of Carbohydrate Biosynthesis. In: <i>Handbook of Carbohydrate Engineering</i> . CRC Press, Yarema, K.J., ed. 2005. Chapter 1, pg 1-48; Figure 1.3; pg 16, para 1-2	45-47
Y	US 2008/0227136 A1 (PLA et al.) 18 September 2008 (18.09.2008) abstract; para [0377]; Fig. 1	61
Y	RITZENTHALER et al. Reevaluation of the effects of brefeldin A on plant cells using tobacco Bright Yellow 2 cells expressing Golgi-targeted green fluorescent protein and COPI antisera. <i>Plant Cell</i> 2002, 14(1):237-261; abstract; pg 237, para 1	62-63
Y	DRECKTRAH et al. Inhibition of a Golgi complex lysophospholipid acyltransferase induces membrane tubule formation and retrograde trafficking. <i>Mol. Biol. Cell</i> 2003, 14(8):3459-3469; abstract; pg 3467, para 4	65
Y	WANG et al. EDEM an ER quality control receptor. <i>Nat. Struct. Biol.</i> 2003, 10(5):319-321; Fig 2	38
A	HOSSLER et al. Systems analysis of N-glycan processing in mammalian cells. <i>PLoS One</i> 2007 2(8):e713, pages 1-17	1-10, 20-26, 30-67
A	NAIRN et al. Regulation of glycan structures in animal tissues: transcript profiling of glycan-related genes. <i>J. Biol. Chem.</i> 2008, 283(25):17298-17313	1-10, 20-26, 30-67

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/31637

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

Group I claims 1-10 and 20-26 are directed to a method for identifying and/or quantifying high mannose and/or hybrid structures in a glycan or glycoprotein preparation and a method for identifying and/or quantifying high mannose and/or hybrid structures in a glycan or glycoprotein preparation.

----- (Continued on extra sheet) -----

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 11/31637

******* Supplemental Box *********Continuation of Box III - Observations where unity of invention is lacking:**

Group II claims 30-55 are directed to a method of evaluating a cell's ability and/or potential to produce high mannose structures, the method comprising: (a) providing a cell, and (b) evaluating two or more components of the cellular machinery selected from the group consisting of: MGAT1 (GlcNAc T1); Alpha mannosidase II; Alpha mannosidase IB; Alpha mannosidase IA; FucT1 -9; Glucosidase GCS1; GANAB; levels of UDPGlcNAc, GDP-Man; UDPUTP; GDP/GTP; Uri dine; Guanosine; GNE (glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine); Golgi UDP phosphatases; UDP-GlcNAc transporter; UAP-1 (UDP-N acetylhexosamine pyrophosphorylase); PGM-3 - phosphoglucomutase 3; NAGK- N-acetyl-D-glucosamine kinase; GNPNAT1 - glucosaminophosphate N-acetyltransferase 1; UGP-2 - UDP-glucose pyrophosphorylase 2; UGDH - UDPglucose 6-dehydrogenase; GAIK -1 - Galactokinase-1; PGM -1 - Phosphoglucomutase-1; GCKGlucokinase; a Chaparones (BiP, SNARE, cpn's, hsp's); EDEM (ER degrading mannosidase-like protein); MANEA; Mannose receptor; Golgi architecture; Golgi lipid content (sphingolipid, cholesterol content); A1P1, VIP36, wherein the result of the evaluation is indicative of the high mannose glycan content or pattern present in a glycoprotein produced by the cell.

Group III claims 56-67 are directed a method for modulating the amount or pattern of high mannose structures of a recombinant glycoprotein, the method comprising: (a) providing a host cell genetically engineered to express a subject glycoprotein, and (b) culturing the cell under conditions to express the recombinant protein, wherein the host cell is subject to a manipulation that modulates one or more components of the cellular machinery described herein.

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is a method for identifying and/or quantifying high mannose and/or hybrid structures in a glycan or glycoprotein preparation. However, this is not an improvement over the prior art of the document entitled "Glycoprotein Analysis Manual" by Gates et al. (2004) that specifically teaches methods for identifying and/or quantifying high mannose and/or hybrid structures in a glycan or glycoprotein preparation (pg 25-28) including, inter alia, treating the glycoprotein sample with an enzyme that cleaves complex fucosylated glycans from the glycoprotein (pg. 32, pg 70 fucosidases), treating the glycoprotein sample with Endoglycosidase F3 (pg 25, pg 70), and performing performing capillary electrophoresis (CE); reverse phase LC-MS or targeted reverse phase-LC-MS on the treated sample (pg 36).

Group II is directed to a method of evaluating enzymatic components of cells, and has no share special technical feature with Group I or Group III. Group II is directed to a method of genetically engineering a cell in order to manipulate the amount or pattern of high mannose structures in the cell and has no shared special technical feature with either Group I or Group II.

For these reasons, the disclosures lack unity of invention.